Evidence map›Paper›PMID 26467269›Full record

ArticleEuropean journal of heart failure2016

The clinical course of health status and association with outcomes in patients hospitalized for heart failure: insights from ASCEND-HF.

Andrew P Ambrosy, Adrian F Hernandez, Paul W Armstrong, Javed Butler, Allison Dunning, Justin A Ezekowitz, G Michael Felker, Stephen J Greene, Padma Kaul, John J McMurray and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of heart failure, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Self-assessed health status and associated mortality in endocarditis: secondary findings from the POET trial.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2022
    Trial
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Observational
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Andrew P AmbrosyDuke University Medical Center, Durham, NC, USA.
Adrian F HernandezDuke University Medical Center, Durham, NC, USA.
Paul W ArmstrongUniversity of Alberta, Edmonton, Alberta, Canada.
Javed ButlerStony Brook Heart Institute, Stony Brook, NY, USA.
Allison DunningDuke Clinical Research Institute, Durham, NC, USA.
Justin A EzekowitzUniversity of Alberta, Edmonton, Alberta, Canada.
G Michael FelkerDuke University Medical Center, Durham, NC, USA.
Stephen J GreeneDuke University Medical Center, Durham, NC, USA.
Padma KaulUniversity of Alberta, Edmonton, Alberta, Canada.
John J McMurrayUniversity of Glasgow, Glasgow, UK.
Marco MetraUniversity of Brescia, Brescia, Italy.
Christopher M O'ConnorDuke University Medical Center, Durham, NC, USA.
Shelby D ReedDuke Clinical Research Institute, Durham, NC, USA.
Phillip J SchulteDuke Clinical Research Institute, Durham, NC, USA.
Randall C StarlingCleveland Clinic, Cleveland, OH, USA.
W H Wilson TangCleveland Clinic, Cleveland, OH, USA.
Adriaan A VoorsUniversity of Groningen, Groningen, The Netherlands.
Robert J MentzDuke University Medical Center, Durham, NC, USA.

Funding

UNC-Duke Collaborative Clinical Pharmacology Postdoctoral Training Program-Evaluation SupplementT32GM086330 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI KIM L.R. BROUWER, Daniel Gonzalez · 2011 to 2026
$8.5M
NIGMS NIH HHS T32 GM086330
6 · The paper itself

Abstract

aimsA longitudinal and comprehensive analysis of health-related quality of life (HRQOL) was performed during hospitalization for heart failure (HF) or soon after discharge. METHODS AND

resultsA post-hoc analysis was performed of the ASCEND-HF trial. The EuroQOL five dimensions questionnaire (EQ-5D) was administered to study participants at baseline, 24 h, discharge/day 10, and day 30. EQ-5D includes functional dimensions mapped to corresponding utility scores (i.e. 0 = death and 1 = perfect health), and a visual analogue scale (VAS) ranging from 0 (i.e. 'worst imaginable health state') to 100 (i.e. 'best imaginable health state'). The association between baseline and discharge EQ-5D measurements and subsequent clinical outcomes including death and rehospitalization were assessed using multivariable logistic regression and Cox proportional hazards regression. A total of 6943 patients (97%) had complete EQ-5D data at baseline. Mapped utility and VAS scores (mean ± SD) increased over time, respectively, from 0.56 ± 0.23 and 45 ± 22 at baseline to 0.67 ± 0.26 and 58 ± 22 at 24 h and to 0.79 ± 0.20 and 68 ± 22 at discharge, and remained stable at day 30. Lower mapped utility scores at baseline [odds ratio (OR) per 0.1 decrease in utility score 1.03, 95% confidence interval (CI) 1.00-1.06] and discharge (OR 1.10, 95% CI 1.05-1.15) and VAS scores at baseline (OR per 10 point decrease 1.05, 95% CI 1.01-1.09) were significantly associated with increased risk of 30-day all-cause death or HF rehospitalization.

conclusionsPatients hospitalized for HF had severely impaired health status at baseline and, although this improved substantially during admission, health status remained abnormal at discharge.

Indexed as

Health StatusQuality of LifeAgedAged, 80 and overDisease ProgressionFemaleHeart FailureHospitalizationHumansMaleMiddle AgedRandomized Controlled Trials as TopicSurveys and QuestionnairesHeart failureHospitalizationMorbidityMortalityQuality of life

Identifiers

PMID26467269
PMCPMC4801656

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.